PO.CL01.18 · 临床研究
在伊利诺伊州北部代表性不足的少数族裔社区中提高认识并加强低剂量计算机断层扫描筛查的可及性以早期检测肺癌
Promoting awareness and enhancing access to low-dose computed tomography screening for early detection of lung cancer in underrepresented minority communities in Northern Illinois
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:肺癌仍是美国癌症相关死亡的主要原因之一,构成了一个持续存在且不公平的公共卫生挑战。2025年预计将出现约226,650例新发病例和124,730例死亡,其中受影响的以种族和民族上代表性不足的少数族裔社区为甚。其高死亡率部分是由于约75%的新发病例在晚期才被诊断。截至2022年,温尼贝戈县(Winnebago County)和奥格尔县(Ogle County)的年龄调整死亡率分别比全国水平高22%和30%。在美国全国肺癌筛查试验(NLST)中,90.9%的参与者为白人,4.5%为非裔美国人,1.8%为西班牙裔,这凸显了更广泛地实施早期肺癌筛查的必要性。低剂量计算机断层扫描(LDCT)是一种有价值的筛查工具,其使用的电离辐射比常规胸部CT扫描少约90%。
假设/目的:在临床和社区环境中提高对LDCT的认识,将促成更高的早期肺癌检出率、降低死亡率并改善预后。
研究设计:我们采取了多方面的方法,在伊利诺伊州的四个县——温尼贝戈(Winnebago)、布恩(Boone)、奥格尔(Ogle)和斯蒂芬森(Stephenson)——推广低剂量计算机断层扫描(LDCT)筛查。我们通过在以少数族裔为中心的活动中设置展位开展社区外展工作,向社区成员和医生宣传美国预防服务工作组(USPSTF)和美国癌症协会(ACS)制定的LDCT指南。记录了参与者的族裔及其邮政编码。为评估我们工作的影响,我们分析了2015年6月至2025年12月的医院数据,包括LDCT筛查和肺癌病例。
结果:从2015年6月至2026年4月,共举办了28场研讨会和76个公众宣传展位,面向3,055人,其中估计包括335名医生和2,720名吸烟者,以推广LDCT筛查。在13,997例LDCT筛查总数中,我们的外展工作触及了21.5%的西班牙裔和36.5%的非裔美国人。共开展了13,997例LDCT筛查,检出181例肺癌病例,其中110例在我们合作的当地医院被诊断为早期。在所有接受LDCT筛查的个体中,约86%为白人,8%为非裔美国人,2%为西班牙裔,1%为亚裔,其余3%为其他人群。
结论:农村和少数族裔社区在肺癌LDCT筛查中仍代表性不足。因此,持续在农村和少数族裔社区推广肺癌筛查和认识,可能会提高吸烟者中肺癌的早期检出率,而这正是我们研究的主要目标。
查看英文原文 English abstract
Background : Lung cancer remains one of the leading causes of cancer-related deaths in the United States, posing a persistent and inequitable public health challenge. In 2025, an estimated 226,650 new cases and 124,730 deaths are expected, disproportionately affecting racially and ethnically underrepresented minority communities. It's high mortality rate is partially due to the fact that ~75% of new cases are diagnosed in late stages. As of 2022, the age-adjusted mortality rates of Winnebago County and Ogle County are 22% and 30% higher than the national rate respectively. In the National Lung Screening trial (NLST), 90.9% of participants were white, 4.5% were African American, and 1.8% were Hispanic, highlighting the need for more widespread implementation of early-stage lung cancer screening. Low dose computed tomography (LDCT) is a valuable screening tool that utilizes ~90% less ionizing radiation than conventional chest CT scans.
Hypothesis/Aims : Increased awareness of LDCT in clinical and community settings will lead to higher rates of lung cancer detection at early-stages, reduce mortality and improve prognosis.
Study Design : We implemented a multifaceted approach to promote Low-Dose Computed Tomography (LDCT) screenings in four Illinois counties - Winnebago, Boone, Ogle, and Stephenson. We conducted community outreach through booths at minority-centered events, educating community members and physicians on the US Preventive Services Task Force
(USPSTF) and ACS set LDCT guidelines. Participant ethnicity and their zip codes were recorded. To evaluate the impact of our efforts, hospital data from June 2015 to December 2025 were analyzed for LDCT screenings and lung cancer cases.
Results : From June 2015 to April 2026, 28 seminars and 76 public awareness booths targeting 3,055 people, with an estimated 335 physicians and 2,720 smokers were conducted to promote LDCT screening. Our outreach work reached 21.5% of Hispanics and 36.5% of African Americans out of 13,997 total LDCT screenings. There were 13,997 total LDCT screenings conducted, detecting 181 lung cancer cases, with 110 cases being diagnosed at early stages in our partnered local hospitals. Among all individuals who underwent LDCT screenings, ~86% were White, 8% were African American, 2% were Hispanic, and 1% were Asian and the rest 3% were other populations.
Conclusion : Rural and minority communities remain underrepresented in LDCT screenings for lung cancer. Thus, continued efforts to promote lung cancer screening and awareness in rural and minority communities may increase the rate of early detection of lung cancer among smokers, which is the primary goal of our study.
利益披露 Disclosure
S. Saravanaguru Vasanthi, None..
G. Kapetaneas, None..
R. Bahari, None..
S. Sreenivasappa, None..
N. Mardini, None..
S. Martell, None..
J. Ross, None..
Y. Molina, None..
N. Puri, None.